News & Press Releases

Virion Therapeutics Reports Progress Towards HBV Functional Cure with Sustained and Continued HBsAg Declines up to One Year After a Single VRON-0200 Dose From its Phase 1b Study at AASLD’s The Liver Meeting® 2025

11/09/2025

https://www.businesswire.com/news/home/20251109380893/en/Virion-Therapeutics-Reports-Progress-Towards-HBV-Functional-Cure-with-Sustained-and-Continued-HBsAg-Declines-up-to-One-Year-After-a-Single-VRON-0200-Dose-From-its-Phase-1b-Study-at-AASLDs-The-Liver-Meeting-2025
Back to News & Press Releases